Do Benznidazole & Nifurtimox Reverse Chagas Heart Damage?
At a Glance
No, benznidazole and nifurtimox cannot reverse heart damage from Chagas disease. While these medications effectively kill the parasite, they cannot undo the permanent scarring and structural changes that cause Chagasic cardiomyopathy. Treatment instead focuses on standard heart therapies.
In this answer
4 sections
No, unfortunately, antiparasitic medicines like benznidazole and nifurtimox cannot reverse or fix heart damage that has already occurred due to Chagas disease [1][2]. While these medications are highly effective at killing the parasite (Trypanosoma cruzi) that causes the infection, they have not been proven to reverse the structural changes, scarring, or clinical symptoms in the heart once chronic Chagasic cardiomyopathy has developed [3][4]. Learning that this damage is permanent can be incredibly difficult to hear, but understanding exactly why this happens can help you focus on the most effective treatments moving forward.
Why Can’t the Damage Be Reversed?
In the early stages of Chagas disease, the damage to the heart is primarily driven by the active infection and the body’s immune response fighting the parasite. Over years or decades, this prolonged inflammation leads to permanent scarring (fibrosis) and structural changes in the heart muscle. Once this scarring has formed and the heart’s pumping ability or electrical system is compromised, simply removing the parasite does not undo the physical damage [5][6].
The BENEFIT Trial and Antiparasitic Therapy
To understand the role of antiparasitic medication in chronic Chagas disease, researchers conducted a major study called the BENEFIT trial. This trial followed patients who already had established Chagas heart disease.
The trial found that taking benznidazole successfully reduced or cleared the detectable parasites in the blood for most patients [2][7]. However, clearing the parasite did not translate to better heart health [8]. Over a 5-year follow-up period, patients who took benznidazole did not have a lower risk of heart failure, sudden cardiac arrest, the need for pacemakers, or death compared to those who did not take the drug [9][10].
Because the drugs do not improve heart outcomes at this stage, doctors generally do not prescribe benznidazole or nifurtimox to adults primarily to treat established heart damage [11]. However, there are exceptions; for example, antiparasitic medication may still be prescribed to a woman of reproductive age with heart damage to prevent her from passing the parasite to a future baby [12].
When Are Antiparasitic Drugs Most Useful?
Antiparasitic drugs are highly effective when given early in the course of the disease [13]. When benznidazole or nifurtimox is given during the acute phase, to children, or to adults who do not yet show signs of heart disease, it can significantly reduce the risk of ever developing heart damage [14][15]. Early intervention stops the chronic inflammation before permanent scarring occurs [16].
How is Established Heart Damage Treated?
If you have already developed Chagasic cardiomyopathy, your care team will focus on supporting your heart function and managing symptoms rather than trying to cure the parasitic infection. The management of established Chagas heart disease relies on standard, effective heart therapies [11][17], which may include:
- Medications to protect the heart: Drugs like ACE inhibitors, ARBs (angiotensin receptor blockers), ARNIs, and beta-blockers help reduce the workload on your heart and protect the heart muscle.
- Medications for fluid: Diuretics (water pills) help manage fluid buildup and reduce swelling.
- Medications for arrhythmias: Drugs to control irregular heartbeats.
- Blood thinners: To prevent blood clots and reduce the risk of stroke.
- Devices: Pacemakers or implantable cardioverter-defibrillators (ICDs) if the heart’s electrical system is severely damaged [18].
- Advanced care: In very severe, end-stage cases that no longer respond to medication or devices, heart transplantation may be considered.
- Lifestyle changes: Your doctor may also recommend dietary modifications (like reducing sodium) and specific guidelines for physical activity.
Common questions in this guide
Can benznidazole or nifurtimox fix heart damage from Chagas disease?
Why do doctors prescribe antiparasitic drugs for Chagas disease?
How is Chagas heart disease treated if antiparasitic drugs don't work?
What was the BENEFIT trial for Chagas disease?
Are there any reasons to take benznidazole if I already have heart damage?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What specific heart medications are most appropriate for my current level of heart function and symptoms?
- 2.Based on my symptoms, do I need an echocardiogram or EKG to check the extent of the scarring or evaluate my heart's electrical system?
- 3.Since I have Chagasic cardiomyopathy, are there any secondary reasons (such as family planning to prevent congenital transmission) why I should still consider taking an antiparasitic medication?
- 4.What specific lifestyle modifications, such as changes in diet or physical activity, can I make to help support my heart health alongside my medications?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (18)
- 1
Chagas Disease: Epidemiology, Diagnosis, and Treatment.
Swett MC, Rayes DL, Campos SV, Kumar RN
Current cardiology reports 2024; (26(10)):1105-1112 doi:10.1007/s11886-024-02113-7.
PMID: 39115799 - 2
Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy.
Morillo CA, Marin-Neto JA, Avezum A, et al.
The New England journal of medicine 2015; (373(14)):1295-306 doi:10.1056/NEJMoa1507574.
PMID: 26323937 - 3
Chagas cardiomyopathy: The potential effect of benznidazole treatment on diastolic dysfunction and cardiac damage in dogs chronically infected with Trypanosoma cruzi.
Santos FM, Mazzeti AL, Caldas S, et al.
Acta tropica 2016; (161()):44-54.
PMID: 27215760 - 4
Beneficial effects of benznidazole in Chagas disease: NIH SaMi-Trop cohort study.
Cardoso CS, Ribeiro ALP, Oliveira CDL, et al.
PLoS neglected tropical diseases 2018; (12(11)):e0006814 doi:10.1371/journal.pntd.0006814.
PMID: 30383777 - 5
Transplantation for chagas' disease: closing the knowledge gap.
La Hoz RM
Current opinion in infectious diseases 2022; (35(5)):397-403 doi:10.1097/QCO.0000000000000868.
PMID: 35942849 - 6
Updated review on the pathophysiology of Chagas cardiomyopathy.
Pech-Aguilar AG, Haro-Álvarez AP, Rosado-Vallado ME
Revista medica del Instituto Mexicano del Seguro Social 2020; (58(3)):328-334 doi:10.24875/RMIMSS.M20000037.
PMID: 34002992 - 7
Successful treatment of suspected early form of chronic Chagas cardiomyopathy: a case report.
Lu N, Werry D, Chapman M, et al.
European heart journal. Case reports 2022; (6(10)):ytac403 doi:10.1093/ehjcr/ytac403.
PMID: 36381253 - 8
Effects of Trypanocidal Treatment on Echocardiographic Parameters in Chagas Cardiomyopathy and Prognostic Value of Wall Motion Score Index: A BENEFIT Trial Echocardiographic Substudy.
Schmidt A, Dias Romano MM, Marin-Neto JA, et al.
Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography 2019; (32(2)):286-295.e3 doi:10.1016/j.echo.2018.09.006.
PMID: 30420161 - 9
Chronic Chagas cardiomyopathy: a review of the main pathogenic mechanisms and the efficacy of aetiological treatment following the BENznidazole Evaluation for Interrupting Trypanosomiasis (BENEFIT) trial.
Rassi A, Marin JA, Rassi A
Memorias do Instituto Oswaldo Cruz 2017; (112(3)):224-235 doi:10.1590/0074-02760160334.
PMID: 28225900 - 10
[The third and new face of Chagas disease].
Pays JF
Bulletin de la Societe de pathologie exotique (1990) 2016; (109(3)):139-42 doi:10.1007/s13149-016-0507-4.
PMID: 27376642 - 11
Prognosis of chronic Chagas heart disease and other pending clinical challenges.
Torres RM, Correia D, Nunes MDCP, et al.
Memorias do Instituto Oswaldo Cruz 2022; (117()):e210172 doi:10.1590/0074-02760210172.
PMID: 35674528 - 12
Prevention of congenital chagas disease by trypanocide treatment in women of reproductive age: A meta-analysis of observational studies.
Moraes FCA, Souza MEC, Dal Moro L, et al.
PLoS neglected tropical diseases 2024; (18(9)):e0012407 doi:10.1371/journal.pntd.0012407.
PMID: 39236037 - 13
Time and dose-dependence evaluation of nitroheterocyclic drugs for improving efficacy following Trypanosoma cruzi infection: A pre-clinical study.
Mazzeti AL, Diniz LF, Gonçalves KR, et al.
Biochemical pharmacology 2018; (148()):213-221 doi:10.1016/j.bcp.2018.01.005.
PMID: 29309767 - 14
Chagas Disease.
Hochberg NS, Montgomery SP
Annals of internal medicine 2023; (176(2)):ITC17-ITC32 doi:10.7326/AITC202302210.
PMID: 36780647 - 15
Impact of antiparasitic therapy on cardiovascular outcomes in chronic Chagas disease. A systematic review and meta-analysis.
Rassi A, Grimshaw A, Sarwal A, et al.
EClinicalMedicine 2025; (79()):102972 doi:10.1016/j.eclinm.2024.102972.
PMID: 39810938 - 16
The expression of immune response genes in patients with chronic Chagas disease is shifted toward the levels observed in healthy subjects as a result of treatment with Benznidazole.
Gómez I, Egui A, Palacios G, et al.
Frontiers in cellular and infection microbiology 2024; (14()):1439714 doi:10.3389/fcimb.2024.1439714.
PMID: 39119291 - 17
Unraveling the Missing Pieces: Exploring the Gaps in Understanding Chagas Cardiomyopathy.
Veluswami K, Rao S, Aggarwal S, et al.
Cureus 2024; (16(8)):e66955 doi:10.7759/cureus.66955.
PMID: 39280489 - 18
Diagnosis and Management of Chagas Cardiomyopathy in the United States.
Benck L, Kransdorf E, Patel J
Current cardiology reports 2018; (20(12)):131 doi:10.1007/s11886-018-1077-5.
PMID: 30311008
This page is for informational purposes only and does not replace professional medical advice. Always consult your cardiologist or infectious disease specialist about treatment options for Chagasic cardiomyopathy.
Get notified when new evidence is published on American trypanosomiasis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.